darizmetinib   Click here for help

GtoPdb Ligand ID: 12376

Synonyms: example 63 [WO2019149738A1] | HRX-0215 | HRX-215 | HRX215
Compound class: Synthetic organic
Comment: This is the chemical structure for the INN darizmetinib. This structure is claimed in HepaRegeniX's patent WO2019149738A1, as a mitogen-activated protein kinase kinase 4 (MKK4) inhibitor [3]. The association of darizmetinib with HepaRegeniX's lead MKK4 inhibitor HRX215 was disclosed in May 2026 [1]. MKK4 is a key regulator of liver regeneration that operates predominantly via MKK7 and JNK1. Inhibition of MKK4 accelerates and enhances the liver's natural regenerative capacity [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 126.08
Molecular weight 457.1
XLogP 3.83
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCS(=O)(=O)Nc1c(F)ccc(c1F)C(=O)c1[nH]nc2c1cc(cn2)c1ccncc1
Isomeric SMILES CCCS(=O)(=O)Nc1c(ccc(c1F)C(=O)c1c2cc(cnc2n[nH]1)c1ccncc1)F
InChI InChI=1S/C21H17F2N5O3S/c1-2-9-32(30,31)28-19-16(22)4-3-14(17(19)23)20(29)18-15-10-13(11-25-21(15)27-26-18)12-5-7-24-8-6-12/h3-8,10-11,28H,2,9H2,1H3,(H,25,26,27)
InChI Key WBNMARNYIFMNEP-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
The MKK4 inhibitor HRX215 was progressed to phase 1, first-in-human evaluation in August 2021. It was subsequently evaluated for efficacy as a treatment for acute and chronic liver diseases. In September 2026 the US FDA granted orphan drug status, for the prevention of post‑hepatectomy liver failure [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06638502 Safety of HRX215 in Patients After Minor and Major Liver Resection Phase 1/Phase 2 Interventional HepaRegeniX GmbH
NCT07612007 HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization Phase 2 Interventional Mayo Clinic